SG11201501920PA - Diagnosis, prevention and treatment of diseases of the joint - Google Patents

Diagnosis, prevention and treatment of diseases of the joint

Info

Publication number
SG11201501920PA
SG11201501920PA SG11201501920PA SG11201501920PA SG11201501920PA SG 11201501920P A SG11201501920P A SG 11201501920PA SG 11201501920P A SG11201501920P A SG 11201501920PA SG 11201501920P A SG11201501920P A SG 11201501920PA SG 11201501920P A SG11201501920P A SG 11201501920PA
Authority
SG
Singapore
Prior art keywords
diagnosis
diseases
prevention
joint
treatment
Prior art date
Application number
SG11201501920PA
Inventor
Dirk Vetter
Ulrich Hersel
Kennett Sprogøe
Nora Kaluza
Oliver Keil
Guillaume Maitro
Harald Rau
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of SG11201501920PA publication Critical patent/SG11201501920PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
SG11201501920PA 2012-10-11 2013-10-08 Diagnosis, prevention and treatment of diseases of the joint SG11201501920PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12188227 2012-10-11
PCT/EP2013/070949 WO2014056915A1 (en) 2012-10-11 2013-10-08 Diagnosis, prevention and treatment of diseases of the joint

Publications (1)

Publication Number Publication Date
SG11201501920PA true SG11201501920PA (en) 2015-04-29

Family

ID=47115335

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501920PA SG11201501920PA (en) 2012-10-11 2013-10-08 Diagnosis, prevention and treatment of diseases of the joint

Country Status (14)

Country Link
US (1) US10980860B2 (en)
EP (1) EP2906245B1 (en)
JP (1) JP6355636B2 (en)
CN (1) CN104755104A (en)
AU (2) AU2013328774B2 (en)
BR (1) BR112015007814B1 (en)
CA (1) CA2885169C (en)
HK (2) HK1208813A1 (en)
IL (3) IL237649B (en)
MX (2) MX363462B (en)
MY (1) MY186106A (en)
RU (1) RU2682676C2 (en)
SG (1) SG11201501920PA (en)
WO (1) WO2014056915A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2988732T3 (en) * 2013-04-22 2023-06-26 Ascendis Pharma As Modified hydrogels
CA2924661A1 (en) * 2013-10-08 2015-04-16 Ascendis Pharma Osteoarthritis Division A/S Hydrogel-linked il-1ra prodrug
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
KR20230015517A (en) * 2016-03-01 2023-01-31 아센디스 파마 본 디지즈 에이/에스 Pth prodrugs
IL265591B2 (en) 2016-09-29 2023-12-01 Ascendis Pharma Bone Diseases As Dosage regimen for a controlled-release pth compound
MX2019003182A (en) 2016-09-29 2019-08-05 Ascendis Pharma Bone Diseases As Pth compounds with low peak-to-trough ratios.
BR112019009019A2 (en) 2016-11-08 2019-07-09 Regeneron Pharma steroids and protein conjugates thereof
JOP20190245A1 (en) 2017-04-20 2019-10-15 Novartis Ag Sustained release delivery systems comprising traceless linkers
JP7364471B2 (en) 2017-05-18 2023-10-18 レゲネロン ファーマシューティカルス，インコーポレーテッド Cyclodextrin protein drug conjugate
KR20210008008A (en) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 Anti-MSR1 antibodies and methods of use thereof
US20210330807A1 (en) * 2018-09-26 2021-10-28 Ascendis Pharma A/S Novel hydrogel conjugates
TW202027794A (en) 2018-10-03 2020-08-01 瑞士商諾華公司 Sustained delivery of angiopoetin-like 3 polypeptides
IT201800009444A1 (en) * 2018-10-15 2020-04-15 Fidia Farm Spa CONJUGATES BETWEEN HYALURONIC ACID AND AMINOBISPHOSPHONATES AND THEIR THERAPEUTIC USE
WO2020254609A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
AU2021269007A1 (en) * 2020-05-04 2022-11-24 Ascendis Pharma A/S Hydrogel irradiation
WO2023096899A1 (en) * 2021-11-24 2023-06-01 Amacathera Hydrogel pharmaceutical compositions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
JP2002519333A (en) * 1998-06-30 2002-07-02 アムジエン・インコーポレーテツド Thermosensitive biodegradable hydrogels for sustained release delivery of biologically active substances
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
CA2479810A1 (en) 2002-04-04 2003-10-16 Enzon, Inc. Polymeric acyl derivatives of indoles
AU2004228793B2 (en) 2003-04-08 2009-10-08 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
US7842667B2 (en) * 2003-12-22 2010-11-30 Regentis Biomaterials Ltd. Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
KR101234476B1 (en) * 2004-03-05 2013-02-18 덴끼 가가꾸 고교 가부시키가이샤 Hyaluronic acid/methotrexate compound
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
ITPD20050146A1 (en) * 2005-05-20 2006-11-21 Fidia Farmaceutici RE-ABSORBABLE FILLERS CONSISTING OF LIPOSOMAS AND HYALURONIC ACID AND OR ITS DERIVATIVES
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CA2677290A1 (en) 2007-02-05 2008-08-14 Nicox S.A. Nitric oxide releasing steroids
WO2009045539A2 (en) 2007-10-05 2009-04-09 Nektar Therapeutics Al, Corporation Oligomer-corticosteroid conjugates
LT2237799T (en) * 2008-02-01 2019-07-25 Ascendis Pharma A/S Prodrug comprising a self-cleavable linker
MX344559B (en) 2008-04-29 2016-12-20 Ascendis Pharma As Pegylated recombinant human growth hormone compounds.
MX2011008963A (en) 2009-03-05 2012-02-01 Ascendis Pharma As Interferon alpha carrier prodrugs.
WO2011009047A2 (en) 2009-07-16 2011-01-20 Ta Tung Yuan Il-1ra-polymer conjugates
WO2011012715A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
US20120191039A1 (en) 2009-07-31 2012-07-26 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
WO2011012722A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
US9597412B2 (en) * 2011-03-16 2017-03-21 University Of Delaware Injectable delivery system for heparan-binding growth factors

Also Published As

Publication number Publication date
CA2885169A1 (en) 2014-04-17
AU2013328774B2 (en) 2017-11-30
EP2906245A1 (en) 2015-08-19
AU2013328774A1 (en) 2015-04-02
MX2019003249A (en) 2019-07-04
IL265774B (en) 2020-05-31
WO2014056915A1 (en) 2014-04-17
IL265774A (en) 2019-06-30
HK1208813A1 (en) 2016-03-18
US20150290337A1 (en) 2015-10-15
MX363462B (en) 2019-03-25
HK1209618A1 (en) 2016-04-08
CA2885169C (en) 2021-06-22
BR112015007814A2 (en) 2017-07-04
US10980860B2 (en) 2021-04-20
MY186106A (en) 2021-06-22
IL237649A0 (en) 2015-04-30
MX2015004330A (en) 2015-07-06
BR112015007814B1 (en) 2022-04-19
RU2015117539A (en) 2016-12-10
IL260579A (en) 2018-10-31
IL260579B (en) 2019-05-30
CN104755104A (en) 2015-07-01
IL237649B (en) 2018-08-30
AU2017276235A1 (en) 2018-01-18
EP2906245B1 (en) 2021-01-13
RU2682676C2 (en) 2019-03-20
JP2015534571A (en) 2015-12-03
JP6355636B2 (en) 2018-07-11

Similar Documents

Publication Publication Date Title
IL265774B (en) Diagnosis, prevention and treatment of diseases of the joint
EP2890440A4 (en) Devices and methods for the treatment of vascular disease
IL239368A0 (en) Ppar-sparing thiazolidiones and combinations for the treatment of neurodegenerative diseases
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
EP2867239A4 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
HK1201045A1 (en) Compositions and methods for the diagnosis and treatment of tumor
EP3013425A4 (en) Treatment and diagnosis of ocular disease
HK1216721A1 (en) Uses and methods for the treatment of liver diseases or conditions
IL234093A0 (en) Oral unit dosage forms and uses of same for the treatment of gaucher disease
EP2943593A4 (en) Diagnosis and treatment of viral diseases
HK1223280A1 (en) Human plgf-2 for the prevention or treatment of heart failure plgf-2
HK1188565A1 (en) Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans
AU2012900775A0 (en) Therapeutic and diagnostic agents
GB201204744D0 (en) Therapeutic and diagnostic target
GB201204754D0 (en) Therapeutic and diagnostic target
GB201204664D0 (en) Therapeutic and diagnostic target
GB201204658D0 (en) Therapeutic and diagnostic target
GB201204578D0 (en) Therapeutic and diagnostic target
GB201204567D0 (en) Therapeutic and diagnostic target
GB201204561D0 (en) Therapeutic and diagnostic target
GB201204491D0 (en) Therapeutic and diagnostic target
GB201204483D0 (en) Therapeutic and diagnostic target
GB201204478D0 (en) Therapeutic and diagnostic target
GB201204389D0 (en) Therapeutic and diagnostic target
GB201204361D0 (en) Therapeutic and diagnostic target